Literature DB >> 30233871

Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function.

Kai Hu1, Dan Liu1, Tim Salinger1, Daniel Oder1, Stefan Knop2, Georg Ertl1, Frank Weidemann3, Stefan Frantz1, Stefan Störk1, Peter Nordbeck1.   

Abstract

BACKGROUND: This study aimed to explore the value of cardiac biomarker [serum high sensitive troponin T (hs-TNT) and N-terminal pro-brain natriuretic peptide (NT-proBNP)] measurement in the differential diagnosis of infiltrative cardiomyopathy patients [Friedreich's ataxia (FA), Fabry disease (FD) and light-chain (AL) cardiac amyloidosis (CA)] with preserved left ventricular (LV) systolic function.
METHODS: Between 2012 and 2014, all consecutive patients presenting at our center with infiltrative cardiomyopathy and concomitant symmetrical LV hypertrophy as well as preserved LV systolic function were included in this study. Serum hs-TNT and NT-proBNP, morphologic and functional features derived from echocardiography and cardiac magnetic resonance imaging (cMRI) examinations were compared among these patients.
RESULTS: A total of 57 patients (FA 20, FD 23 and CA 14) were included. Hs-TNT and NT-proBNP levels were significantly higher in the CA group [median: hs-TNT 98 pg/mL, NT-proBNP 4,110 pg/mL] than in the FA group [hs-TNT 14 pg/mL, NT-proBNP 40 pg/mL] and FD group [hs-TNT 18 pg/mL, NT-proBNP 131 pg/mL, both P<0.001]. There was a negative correlation between NT-proBNP and estimated glomerular filtration rate (eGFR) in CA patients (r=-0.72, P=0.012). Both hs-TNT >60 pg/mL (sensitivity 0.79, specificity 0.93) and NT-proBNP >1,000 pg/mL (sensitivity 0.91, specificity 0.93) excellently differentiated CA from FA and FD.
CONCLUSIONS: Increased hs-TNT and NT-proBNP levels are suggestive of CA diagnosis among patients with infiltrative cardiomyopathy and preserved LV ejection fraction.

Entities:  

Keywords:  Fabry disease (FD); Friedreich’s ataxia; cardiac amyloidosis (CA); diagnosis

Year:  2018        PMID: 30233871      PMCID: PMC6129925          DOI: 10.21037/jtd.2018.07.56

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  24 in total

1.  It's time for a change to a troponin standard.

Authors:  A S Jaffe; J Ravkilde; R Roberts; U Naslund; F S Apple; M Galvani; H Katus
Journal:  Circulation       Date:  2000-09-12       Impact factor: 29.690

2.  Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.

Authors:  Nicolas Guérard; Daniel Oder; Peter Nordbeck; Christian Zwingelstein; Olivier Morand; Richard W D Welford; Jasper Dingemanse; Christoph Wanner
Journal:  Clin Pharmacol Ther       Date:  2017-08-28       Impact factor: 6.875

Review 3.  BNP as a biomarker in heart disease.

Authors:  Olli Vuolteenaho; Minna Ala-Kopsala; Heikki Ruskoaho
Journal:  Adv Clin Chem       Date:  2005       Impact factor: 5.394

4.  Cardiac troponin I: evaluation I of a biomarker for the diagnosis of heart disease in the dog.

Authors:  D P Spratt; R J Mellanby; N Drury; J Archer
Journal:  J Small Anim Pract       Date:  2005-03       Impact factor: 1.522

5.  Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Authors:  Giovanni Palladini; Carlo Campana; Catherine Klersy; Alessandra Balduini; Giovanbattista Vadacca; Vittorio Perfetti; Stefano Perlini; Laura Obici; Edoardo Ascari; Gianvico Melzi d'Eril; Remigio Moratti; Giampaolo Merlini
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

6.  Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease.

Authors:  Caroline J Coats; Valentina Parisi; Monica Ramos; Kalaiarasi Janagarajan; Constantinos O'Mahony; Anne Dawnay; Robin H Lachmann; Elaine Murphy; Atul Mehta; Derralynn Hughes; Perry M Elliott
Journal:  Am J Cardiol       Date:  2012-10-04       Impact factor: 2.778

7.  Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins.

Authors:  Angela Dispenzieri; Robert A Kyle; Morie A Gertz; Terry M Therneau; Wayne L Miller; Krishnaswamy Chandrasekaran; Joseph P McConnell; Mary F Burritt; Allan S Jaffe
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

8.  Differentiation of infiltrative cardiomyopathy from hypertrophic cardiomyopathy using high-sensitivity cardiac troponin T: a case-control study.

Authors:  Toru Kubo; Yuichi Baba; Takayoshi Hirota; Katsutoshi Tanioka; Naohito Yamasaki; Shigeo Yamanaka; Tatsuo Iiyama; Naoko Kumagai; Takashi Furuno; Tetsuro Sugiura; Hiroaki Kitaoka
Journal:  BMC Cardiovasc Disord       Date:  2015-06-16       Impact factor: 2.298

9.  Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping.

Authors:  Daniel M Sado; Steven K White; Stefan K Piechnik; Sanjay M Banypersad; Thomas Treibel; Gabriella Captur; Marianna Fontana; Viviana Maestrini; Andrew S Flett; Matthew D Robson; Robin H Lachmann; Elaine Murphy; Atul Mehta; Derralynn Hughes; Stefan Neubauer; Perry M Elliott; James C Moon
Journal:  Circ Cardiovasc Imaging       Date:  2013-04-05       Impact factor: 7.792

10.  Marked elevation of B-type natriuretic peptide in patients with heart failure and preserved ejection fraction.

Authors:  Samuel Tate; Andrea Griem; Blythe Durbin-Johnson; Clifton Watt; Saul Schaefer
Journal:  J Biomed Res       Date:  2014-06-07
View more
  1 in total

1.  A Proteomics-Based Analysis Reveals Predictive Biological Patterns in Fabry Disease.

Authors:  Abdellah Tebani; Wladimir Mauhin; Lenaig Abily-Donval; Céline Lesueur; Marc G Berger; Yann Nadjar; Juliette Berger; Oliver Benveniste; Foudil Lamari; Pascal Laforêt; Esther Noel; Stéphane Marret; Olivier Lidove; Soumeya Bekri
Journal:  J Clin Med       Date:  2020-05-02       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.